IXJ
iShares Global Healthcare ETF · PSE
- Category Equity
- Expense Ratio 0.42%
- Listing Date Nov 16, 2001
- Volume 63,360.0
- Market Cap (AUM) $3,920.82M
Performance
+1.21%
1W
+0.09%
1M
+0.2%
3M
+11.67%
6M
+4.42%
YTD
+5.88%
1Y
Top Holdings
-
Name
Symbol%Assets
- Eli Lilly and CompanyLLY8.50%
- UnitedHealth Group IncorporatedUNH6.15%
- Novo Nordisk A/S Class BNOVO.B5.70%
- Johnson & JohnsonJNJ4.74%
- Merck & Co., Inc.MRK4.51%
- AbbVie, Inc.ABBV3.93%
- AstraZeneca PLCAZN3.25%
- Thermo Fisher Scientific Inc.TMO3.06%
- Novartis AGNOVN2.79%
- Abbott LaboratoriesABT2.54%
Technical Analysis of IXJ 2024-05-03
Overview:
In analyzing the technical indicators for IXJ over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for potential investo...
Recent News & Updates
- 2021-06-23 00:45
Medical Device ETF Debuts(Yahoo Finance)
- 2019-11-03 22:20
Eaton Vance Worldwide Health Sciences Fund Buys 2 Stocks(Yahoo Finance)
- 2019-08-06 03:45
- 2019-06-11 20:28
Traders Look to Buy Global Health Care Stocks(Investopedia)
- 2018-08-09 00:45
Investors Flocked to Healthcare ETFs in July(Yahoo Finance)
- 2018-08-01 22:47
5 Strong Healthcare ETFs to Buy(Yahoo Finance)
- 2018-03-29 04:30
BlackRock Announces Share Split for Four iShares ETFs(Yahoo Finance)
- 2018-01-24 20:38
Analysts Estimates for Pfizers 4Q17 Earnings(Marketrealist)
- 2018-01-18 04:30
Merck & Co.s Business Segments and Performance in 3Q17(Marketrealist)
- 2018-01-08 21:48
7 Best Healthcare ETFs for 2018(Yahoo Finance)
- 2017-10-02 01:27
9 Million American Children Lost Funding For Their Insurance(Yahoo Finance)
- 2017-09-11 21:06
- 2017-09-10 20:36
Whats Gilead Sciences Valuation?(Marketrealist)
- 2017-09-04 21:07
Performance of AstraZenecas CVMD Segment in 2Q17(Marketrealist)
- 2017-08-29 03:05
Bristol-Myers Squibbs Revenues in 2Q17(Marketrealist)
- 2017-08-22 21:07
Inside Incytes Jakafi Performance in 2Q17(Marketrealist)
- 2017-07-26 03:09
AstraZenecas 2Q17 Earnings: Analysts Estimates(Marketrealist)
- 2017-07-24 19:37
Major Developments for Johnson and Johnson(Marketrealist)
- 2017-07-17 22:37
Analyst Ratings and Recommendations for Novartis Post 2Q17(Marketrealist)
- 2017-07-16 22:37
Inside Allergans International Business(Marketrealist)
- 2017-07-10 19:37
How Celgene Stock Performed in 2Q17(Marketrealist)
- 2017-07-04 19:37
Johnson & Johnsons Medical Devices Business in 1Q17(Marketrealist)
- 2017-07-03 22:36
Performance of Mercks Diabetes Drugs in 1Q17(Marketrealist)
- 2017-06-27 21:06
Pfizers Geographical Performance in 1Q17(Marketrealist)
- 2017-06-21 19:36
Changes in Bristol-Myers Squibbs Profitability 1Q17(Marketrealist)
- 2017-06-04 22:36
Performance of Elanco in 1Q17(Marketrealist)
- 2017-05-30 19:36
- 2017-05-30 05:05
Johnson & Johnsons Business Segments in 1Q17(Marketrealist)
- 2017-05-29 02:05
AstraZenecas Segment-by-Segment Performance in 1Q17(Marketrealist)
- 2017-05-24 21:06
Performance of Mercks Animal Health Segment in 1Q17(Marketrealist)
- 2017-05-07 23:26
Allergans 1Q17 Earnings: Analysts Estimates(Marketrealist)
- 2017-05-05 05:36
Pfizers Geographical Performance in 1Q17(Marketrealist)
- 2017-04-25 21:07
GlaxoSmithKlines 1Q17 Estimates: Consumer Healthcare(Marketrealist)
- 2017-04-25 04:28
What Analysts Expect of Bristol-Myers Squibbs 1Q17 Earnings(Marketrealist)
- 2017-04-23 19:38
Novartiss 1Q17 Estimates for Sandoz(Marketrealist)
- 2017-04-13 03:05
Johnson & Johnsons Revenue Estimates: Expect Growth!(Marketrealist)
- 2017-04-09 21:06
Examining Gilead Sciences 1Q17 Performance(Marketrealist)
- 2017-04-07 01:35
Assessing Johnson & Johnsons 1Q17 Performance(Marketrealist)
- 2017-04-04 19:36
Must-Know Corporate and Pipeline Developments for Pfizer(Marketrealist)
- 2017-04-02 19:36
How Eli Lillys New Products Performed in 2016(Marketrealist)
Page 1 of 3
previousnext